1,285 reports of this reaction
1.7% of all FILGRASTIM reports
#15 most reported adverse reaction
PANCYTOPENIA is the #15 most commonly reported adverse reaction for FILGRASTIM, manufactured by Amgen, Inc. There are 1,285 FDA adverse event reports linking FILGRASTIM to PANCYTOPENIA. This represents approximately 1.7% of all 76,865 adverse event reports for this drug.
Patients taking FILGRASTIM who experience pancytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PANCYTOPENIA is a less commonly reported adverse event for FILGRASTIM, but still significant enough to appear in the safety profile.
In addition to pancytopenia, the following adverse reactions have been reported for FILGRASTIM:
The following drugs have also been linked to pancytopenia in FDA adverse event reports:
PANCYTOPENIA has been reported as an adverse event in 1,285 FDA reports for FILGRASTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PANCYTOPENIA accounts for approximately 1.7% of all adverse event reports for FILGRASTIM, making it a notable side effect.
If you experience pancytopenia while taking FILGRASTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.